This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechnology: Archive
Alnylam (ALNY) Soars as Heart Disease Drug Study Meets Goals
by Zacks Equity Research
Alnylam (ALNY) soars as its phase III study, seeking to expand Anvuttra's label to include the treatment of ATTR amyloidosis with cardiomyopathy, achieves primary and all secondary endpoints.
ALNYPositive Net Change CGENNegative Net Change ANVSNegative Net Change ALXONegative Net Change
biotechnology biotechs medical pharmaceuticals
Company News for Jun 25, 2024
by Zacks Equity Research
Companies In The News Are: RXO, UPS, LLY, ALNY, META, AAPL.
ALNYPositive Net Change AAPLNegative Net Change LLYPositive Net Change UPSNegative Net Change METANegative Net Change RXONegative Net Change
biotechnology pharmaceuticals social-media tech-stocks transportation
Bristol Myers' (BMY) Krazati Gets FDA Nod for Colorectal Cancer
by Zacks Equity Research
Bristol Myers (BMY) wins FDA approval for Krazati, in combination with Erbitux, as a targeted treatment option for adult patients with KRASG12C-mutated locally advanced or metastatic colorectal cancer.
BMYNegative Net Change LGNDPositive Net Change NERVPositive Net Change ALXONegative Net Change
biotechnology biotechs medical pharmaceuticals
Intra-Cellular's (ITCI) Caplyta Boosts Sales, Dependence a Woe
by Zacks Equity Research
Intra-Cellular (ITCI) is witnessing strong Caplyta sales, driven by an increasing prescription rate. However, the company is heavily dependent on Caplyta sales for growth, which is a concern.
AXSMPositive Net Change ANVSNegative Net Change ALXONegative Net Change
biotechnology biotechs medical pharmaceuticals
Company News for Jun 24, 2024
by Zacks Equity Research
Companies In The News Are: FDS, SRPT, HTZ, ASAN.
HTZPositive Net Change FDSPositive Net Change SRPTPositive Net Change ASANNegative Net Change
biotechnology business-services internet transportation
Gilead (GILD) Up as Twice-Yearly HIV Shot Prevents Infection
by Zacks Equity Research
Gilead's (GILD) twice-yearly, subcutaneous lenacapavir has demonstrated its potential as a new tool to help prevent HIV infections with zero infections and 100% efficacy. Shares gain.
GSKPositive Net Change GILDPositive Net Change LGNDPositive Net Change ALXONegative Net Change
biotechnology biotechs medical pharmaceuticals
JAZZ Falls as Suvecaltamide Tremor Study Fails to Meet Goals
by Zacks Equity Research
JAZZ shares are down 5% as it fails to achieve statistical significance on the primary and key secondary endpoint in a mid-stage tremor study on suvecaltamide.
JAZZNegative Net Change ANVSNegative Net Change ALXONegative Net Change PRAXPositive Net Change
biotechnology biotechs medical pharmaceuticals
Biotech Stock Roundup: ITCI Up on Study Data, ZNTL, OVID Down on Updates & More News
by Zacks Equity Research
Intra-Cellular Therapies (ITCI) and Zentalis Pharmaceuticals, Inc. (ZNTL) are in the spotlight following pipeline and regulatory updates, respectively.
AMGNPositive Net Change MRNANegative Net Change OVIDPositive Net Change ZNTLPositive Net Change
biotechnology biotechs medical pharmaceuticals vaccines
Here's Why Eli Lilly (LLY) is Probably the Best Drug Stock Now
by Kinjel Shah
Eli Lilly (LLY) enjoys strong fundamentals and is expected to consistently do well, mainly supported by its new drugs and its solid pipeline.
JNJPositive Net Change PFEPositive Net Change NVONegative Net Change LLYPositive Net Change
biotechnology cancer gene-therapy
Zacks Initiates Coverage of Enzo Biochem With Neutral Recommendation
by Debanjana Dey
Discover why Zacks rates Enzo Biochem as "Neutral", being the first on Wall Street to initiate coverage on the stock. Explore ENZ's notable revenue growth and financial health amid market challenges.
biotechnology biotechs medical
Should You Hold Kodiak Sciences (KOD) Stock in Your Portfolio?
by Zacks Equity Research
Kodiak Sciences (KOD) is evaluating its lead candidate, tarcocimab, in a late-stage study for diabetic retinopathy, which is expected to support a regulatory filing for three eye disease indications.
CGENNegative Net Change KODPositive Net Change ANVSNegative Net Change ALXONegative Net Change
biotechnology biotechs medical pharmaceuticals
Terns (TERN) Gains 13.6% YTD: Will the Momentum Continue?
by Zacks Equity Research
Terns Pharmaceuticals, Inc. (TERN) outperforms the industry year to date on encouraging pipeline progress of its oncology candidate.
NVSPositive Net Change LGNDPositive Net Change ALXONegative Net Change TERNNegative Net Change
biotechnology biotechs medical pharmaceuticals
Day One (DAWN) In-Licenses MabCare Cancer Candidate, Stock Up
by Zacks Equity Research
Day One (DAWN) gains 11% on in-licensing exclusive worldwide rights to MabCare???s MTX-13, which is set to begin clinical studies for adult and pediatric solid tumor indications.
CGENNegative Net Change ANVSNegative Net Change ALXONegative Net Change DAWNNegative Net Change
biotechnology biotechs medical pharmaceuticals
Intra-Cellular (ITCI) Up as Second Depression Study Meets Goals
by Zacks Equity Research
Intra-Cellular (ITCI) gains 10% after achieving key goals in the second late-stage study evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of MDD.
CGENNegative Net Change ANVSNegative Net Change ALXONegative Net Change
biotechnology biotechs medical pharmaceuticals
Regeneron (REGN) Outperforms Industry YTD: What Lies Ahead?
by Zacks Equity Research
Regeneron (REGN) maintains momentum on the back of Dupixent profits and efforts to develop oncology portfolio despite near-term challenges.
REGNPositive Net Change SNYPositive Net Change RHHBYPositive Net Change BAYRYNegative Net Change
biotechnology biotechs medical pharmaceuticals
Aerovate (AVTE) Down as Lead Drug Fails to Meet PAH Study Goals
by Zacks Equity Research
Aerovate's (AVTE) shares plunge 93% as its lead candidate, AV-101, fails to meet the primary and secondary endpoints in the phase IIb/III study to treat pulmonary arterial hypertension patients.
CGENNegative Net Change ANVSNegative Net Change ALXONegative Net Change
biotechnology biotechs medical pharmaceuticals
Roche (RHHBY) Reports Upbeat Data on Columvi From STARGLO Study
by Zacks Equity Research
Roche's (RHHBY) Columvi significantly extends survival in patients with relapsed or refractory diffuse large B-cell lymphoma in the phase III STARGLO study.
RHHBYPositive Net Change LGNDPositive Net Change NERVPositive Net Change ALXONegative Net Change
biotechnology biotechs medical pharmaceuticals
Editas (EDIT) Reports Upbeat New Data From Reni-Cel Studies
by Zacks Equity Research
Editas (EDIT) reports positive new safety and efficacy data from the RUBY and EdiTHAL studies evaluating its investigational gene therapy, reni-cel, for SCD and TDT, respectively.
VRTXPositive Net Change EDITPositive Net Change CRSPNegative Net Change ALXONegative Net Change
biotechnology biotechs crispr gene-editing gene-therapy medical pharmaceuticals
Bristol Myers (BMY) Gets FDA Nod for Label Expansion of Augtyro
by Zacks Equity Research
The FDA approves Bristol Myers' (BMY) cancer drug Augtyro for the treatment of adult and pediatric patients aged 12 years and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion.
BMYNegative Net Change LGNDPositive Net Change NERVPositive Net Change ALXONegative Net Change
biotechnology biotechs medical pharmaceuticals
Shattuck (STTK) Announces Positive Interim Data on Cancer Drug
by Zacks Equity Research
Shattuck (STTK) will now focus on higher-risk myelodysplastic syndromes and TP53 mutant acute myeloid leukemia indications for lead candidate SL-172154, following encouraging interim data from the phase IB dose expansion study.
LGNDPositive Net Change NERVPositive Net Change ALXONegative Net Change STTKNegative Net Change
biotechnology biotechs medical pharmaceuticals
Simulations Plus (SLP) Buys Pro-ficiency Holdings for $100M
by Zacks Equity Research
Simulation Plus (SLP) acquires Pro-ficiency from QHP Capital for $100 million in an all-cash transaction.
NVDANegative Net Change SLPNegative Net Change MSIPositive Net Change ANETNegative Net Change
biotechnology biotechs computers pharmaceuticals tech-stocks
Universal Display Corp. (OLED)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
OLEDNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Regeneron (REGN), SNY Win FDA Nod for Kevzara Label Expansion
by Zacks Equity Research
The FDA approves label expansion of Regeneron (REGN) and Sanofi's Kevzara for the treatment of polyarticular juvenile idiopathic arthritis.
REGNPositive Net Change SNYPositive Net Change NERVPositive Net Change ALXONegative Net Change
biotechnology biotechs medical pharmaceuticals
BM Technologies, Inc. (BMTX) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Apellis (APLS) Up on Upbeat GA Data From Long-Term Syfovre Study
by Zacks Equity Research
Apellis (APLS) rises 3.3% as the treatment of GA patients with Syfovre demonstrates a visual function benefit in a prespecified endpoint at month 36 in a late-stage, long-term extension study.
CGENNegative Net Change APLSNegative Net Change ANVSNegative Net Change ALXONegative Net Change
biotechnology biotechs medical pharmaceuticals